Kolexia
Carassou Philippe Médecine générale
Carassou Philippe
Médecine générale
Hia Legouest
Metz, France
83 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Maladie résiduelle Arthrite Thrombopénie Purpura thrombopénique idiopathique Maladies gastro-intestinales Fièvre

Collaborateurs

Voir plus
Cinquetti Gaël
Cinquetti Gaël
Hôpital Mercy, Ars-Laquenexy, France
Dorvaux Veronique
Dorvaux Veronique
Hôpital Mercy, Ars-Laquenexy, France
Graffin Bruno
Graffin Bruno
Polyclinique Mutualiste Malartic, Ollioules, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Janssen
18 collaboration(s)
Dernière en 2023
B3TSI
15 collaboration(s)
Dernière en 2023
AstraZeneca
6 collaboration(s)
Dernière en 2023
A+A
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Essai Clinique (Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH)   22 février 2024
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023
STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   23 mai 2023
A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
Annual Meeting Abstracts 2022   15 novembre 2022
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
Annual Meeting Abstracts 2022   15 novembre 2022
20. Soins de support | éthique | sciences humaines
Hématologie Congress 2022   30 mars 2022
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica   01 décembre 2021
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
Blood   23 novembre 2021
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood   22 juillet 2021